BR9916576A - Uso de antagonista receptor at-1 ou modulador receptor at-2 para o tratamento de doenças associadas com um aumento de receptores at-1 ou at-2 - Google Patents

Uso de antagonista receptor at-1 ou modulador receptor at-2 para o tratamento de doenças associadas com um aumento de receptores at-1 ou at-2

Info

Publication number
BR9916576A
BR9916576A BR9916576-7A BR9916576A BR9916576A BR 9916576 A BR9916576 A BR 9916576A BR 9916576 A BR9916576 A BR 9916576A BR 9916576 A BR9916576 A BR 9916576A
Authority
BR
Brazil
Prior art keywords
receptors
increase
treatment
diseases associated
receptor
Prior art date
Application number
BR9916576-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Gillian Rosemary Bullock
Marc De Gasparo
Sabina Maria Ganter
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26152118&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9916576(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP98811258A external-priority patent/EP1013273A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR9916576A publication Critical patent/BR9916576A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR9916576-7A 1998-12-23 1999-12-22 Uso de antagonista receptor at-1 ou modulador receptor at-2 para o tratamento de doenças associadas com um aumento de receptores at-1 ou at-2 BR9916576A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98811257 1998-12-23
EP98811258A EP1013273A1 (en) 1998-12-23 1998-12-23 Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
PCT/EP1999/010330 WO2000038676A1 (en) 1998-12-23 1999-12-22 Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors

Publications (1)

Publication Number Publication Date
BR9916576A true BR9916576A (pt) 2001-10-02

Family

ID=26152118

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9916576-7A BR9916576A (pt) 1998-12-23 1999-12-22 Uso de antagonista receptor at-1 ou modulador receptor at-2 para o tratamento de doenças associadas com um aumento de receptores at-1 ou at-2

Country Status (26)

Country Link
EP (3) EP1140071B1 (cs)
JP (2) JP2002533390A (cs)
KR (1) KR100646716B1 (cs)
CN (2) CN1636561A (cs)
AT (2) ATE524176T1 (cs)
AU (4) AU3043000A (cs)
BR (1) BR9916576A (cs)
CA (2) CA2622805C (cs)
CY (2) CY1106581T1 (cs)
CZ (2) CZ293257B6 (cs)
DE (1) DE69935249T2 (cs)
DK (2) DK1140071T3 (cs)
ES (2) ES2373556T3 (cs)
HK (1) HK1038888B (cs)
HU (1) HUP0104780A3 (cs)
ID (1) ID29856A (cs)
IL (5) IL143233A0 (cs)
NO (2) NO328775B1 (cs)
NZ (3) NZ553010A (cs)
PL (1) PL199100B1 (cs)
PT (2) PT1140071E (cs)
RU (3) RU2271809C2 (cs)
SI (2) SI1140071T1 (cs)
SK (1) SK9132001A3 (cs)
TR (7) TR200605472T1 (cs)
WO (1) WO2000038676A1 (cs)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8576801A (en) * 2000-06-22 2002-01-02 Novartis Ag Pharmaceutical compositions
JP4972847B2 (ja) * 2000-10-11 2012-07-11 住友化学株式会社 コラーゲン蓄積抑制剤
WO2002083127A1 (en) * 2001-04-09 2002-10-24 Tokai University Educational System Protein modification-inhibitory compositions
WO2002096883A1 (en) 2001-05-31 2002-12-05 Vicore Pharma Ab Tricyclic compounds useful as angiotensin ii agonists
CA2466659A1 (en) 2001-11-13 2003-05-22 Takeda Chemical Industries, Ltd. Anticancer agents
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
EP1680095A2 (en) * 2003-11-03 2006-07-19 Zentiva, a.s. Valsartan containing formulation
CN101087619B (zh) * 2004-12-24 2012-12-05 西芬克斯医药有限公司 治疗或预防的方法
DK2033629T3 (da) 2004-12-24 2013-02-04 Krka Fast farmaceutisk sammensætning omfattende valsartan
WO2006136916A2 (en) * 2005-06-20 2006-12-28 Glenmark Pharmaceuticals Limited Substantially pure micronized particles of telmisartan and pharmaceutical compositions containing same
GT200600371A (es) 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
ES2246742B1 (es) * 2005-09-06 2007-02-01 Prous Institute For Biomedical Research S.A. Uso de un derivado de imidazol.
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
WO2008120242A1 (en) * 2007-03-29 2008-10-09 Alembic Limited Valsartan tablet formulations
TR200703568A1 (tr) 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formülasyonları
AU2008311053B2 (en) 2007-10-09 2012-08-30 Novartis Ag Pharmaceutical formulation of valsartan
ES2939163T3 (es) * 2007-11-06 2023-04-19 Novartis Ag Composiciones farmacéuticas basadas en superestructuras de antagonista/bloqueante del receptor de angiotensina (ARB) e inhibidor de la endopeptidasa neutra (NEP)
WO2009092052A2 (en) * 2008-01-18 2009-07-23 Massachusetts Eye And Ear Infirmary Methods and compositions for treating polyps
GB0802931D0 (en) * 2008-02-18 2008-03-26 Queen Mary & Westfield College Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal anitbody variable regions
WO2010104485A2 (en) 2009-03-11 2010-09-16 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Valsartan formulations
WO2011102702A2 (en) 2010-02-16 2011-08-25 Krka, D. D., Novo Mesto Process for the preparation of oral solid dosage forms comprising valsartan
EP2455388A1 (en) 2010-11-23 2012-05-23 LanthioPep B.V. Novel angiotensin type 2 (AT2) receptor agonists and uses thereof.
CN102266307B (zh) * 2011-08-01 2012-10-24 海南锦瑞制药股份有限公司 一种缬沙坦胶囊及其制备方法
WO2013098576A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan
WO2013098578A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
EA018867B1 (ru) * 2012-11-01 2013-11-29 Лаборатория Тютор С.А.С.И.Ф.И.А. Способ получения фармацевтической композиции и продукт способа
EP4007592A1 (en) 2019-08-02 2022-06-08 LanthioPep B.V. Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer
EP4295839A1 (en) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Combination of valsartan and indapamide
WO2024026528A1 (en) * 2022-08-02 2024-02-08 Dimerix Bioscience Pty Ltd Dosage regimen for the treatment of copd

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3146168A (en) * 1962-04-10 1964-08-25 Fmc Corp Manufacture of pharmaceutical preparations containing cellulose crystallite aggregates
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
ES2060737T3 (es) * 1988-02-25 1994-12-01 Yamanouchi Europ Bv Procedimiento de preparacion de un granulado farmaceutico.
ES2207091T3 (es) 1989-06-14 2004-05-16 Smithkline Beecham Corporation Acido imidazolil-alquenoico.
IE70593B1 (en) 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
DE122007000050I1 (de) * 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
PT97078B (pt) 1990-03-20 1997-07-31 Sanofi Sa Processo para a preparacao de derivados heterociclicos n-substituidos e de composicoes farmaceuticas que os contem
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IL99246A0 (en) 1990-09-10 1992-07-15 Abbott Lab Angiotensin ii receptor antagonists and pharmaceutical compositions containing them
WO1992005784A1 (en) * 1990-10-02 1992-04-16 Warner-Lambert Company 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists
DE4038335A1 (de) * 1990-12-01 1992-06-04 Boehringer Mannheim Gmbh Neue pyridinderivate, verfahren zu ihrer herstellung und verwendung als arzneimittel
US5614519A (en) * 1991-02-06 1997-03-25 Karl Thomae Gmbh (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists
SI9210098B (sl) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5196537A (en) 1991-03-21 1993-03-23 G. D. Searle & Co. 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
GB9110636D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
DE4132632A1 (de) * 1991-10-01 1993-04-08 Bayer Ag Substituierte imidazolyl-propensaeurederivate
DE4309968A1 (de) * 1993-03-26 1994-09-29 Bayer Ag Phenylglycinamide von heterocyclisch substituierten Phenylessigsäurederivaten
AU675935B2 (en) 1992-04-13 1997-02-27 Astrazeneca Ab Angiotensin II antagonists against disorders associated withimpaired neuronal conduction velocity, especially diabetic neuropathy
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5610153A (en) 1992-12-11 1997-03-11 Ciba-Geigy Corporation Benzazepinone derivatives
EP0673369A1 (de) * 1992-12-11 1995-09-27 Novartis AG Substituierte benzazepinone
DE4309963A1 (de) * 1993-03-26 1994-09-29 Hubert Kamperschroer Faß zum Austragen von Gülle
FR2716882B1 (fr) * 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
DE4408497A1 (de) * 1994-03-14 1995-09-21 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
SK117996A3 (en) 1994-03-17 1997-03-05 Ciba Geigy Ag Pharmaceutical composition for treatment of diabetic nephropathy
DE4432860A1 (de) * 1994-09-15 1996-03-21 Merck Patent Gmbh Imidazopyridine
AU7213296A (en) 1995-10-06 1997-04-30 Ciba-Geigy Ag At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
WO1997031624A1 (en) 1996-02-27 1997-09-04 Purdue Research Foundation Liposomal delivery system
JP4369994B2 (ja) * 1996-02-29 2009-11-25 ノバルティス アクチエンゲゼルシャフト アポトーシスの刺激のためのａｔ▲下１▼レセプターアンタゴニスト
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
DE19628617A1 (de) * 1996-07-16 1998-01-22 Basf Ag Direkttablettierhilfsmittel
RU2243768C2 (ru) 1998-07-10 2005-01-10 Новартис Аг Гипотензивная комбинация валсартана и блокатора кальциевых каналов
HUP0105199A3 (en) 1999-01-26 2004-11-29 Novartis Ag Use of angiotensin ii receptor antagonists for treating acute myocardial infarction
AU8576801A (en) * 2000-06-22 2002-01-02 Novartis Ag Pharmaceutical compositions
US20070123498A1 (en) 2003-10-17 2007-05-31 Shetty Suraj S Combination of organic compounds
JP2009018990A (ja) 2005-10-25 2009-01-29 Univ Kurume Ｃ型肝炎ウイルス由来ペプチド

Also Published As

Publication number Publication date
TR200101784T2 (tr) 2001-10-22
ATE354364T1 (de) 2007-03-15
PT1588706E (pt) 2011-12-21
PT1140071E (pt) 2007-05-31
DE69935249T2 (de) 2007-10-31
IL179017A0 (en) 2007-03-08
DK1588706T3 (da) 2012-01-16
KR100646716B1 (ko) 2006-11-17
AU2003266433B2 (en) 2006-08-10
ES2281978T3 (es) 2007-10-01
NZ587909A (en) 2012-05-25
DK1140071T3 (da) 2007-06-04
CN1331590A (zh) 2002-01-16
CZ20012306A3 (cs) 2001-12-12
IL179016A0 (en) 2007-03-08
NO20100041L (no) 2001-08-16
AU2006203077A1 (en) 2006-08-10
EP2298298A3 (en) 2011-05-11
SK9132001A3 (en) 2002-01-07
JP2002533390A (ja) 2002-10-08
HUP0104780A2 (hu) 2002-04-29
TR200200764T2 (tr) 2002-07-22
AU2003266433A1 (en) 2004-01-08
CA2351357A1 (en) 2000-07-06
EP1140071B1 (en) 2007-02-21
CN1304000C (zh) 2007-03-14
DE69935249D1 (de) 2007-04-05
NO20013143D0 (no) 2001-06-22
WO2000038676A1 (en) 2000-07-06
RU2271809C2 (ru) 2006-03-20
EP1588706A2 (en) 2005-10-26
CA2622805A1 (en) 2000-07-06
CY1112395T1 (el) 2015-12-09
AU2009220022A1 (en) 2009-10-15
TR200805741T2 (tr) 2008-10-21
IL143233A0 (en) 2002-04-21
AU3043000A (en) 2000-07-31
RU2005124363A (ru) 2007-02-10
CZ293257B6 (cs) 2004-03-17
RU2361575C2 (ru) 2009-07-20
CZ297795B6 (cs) 2007-03-28
TR200605471T2 (tr) 2006-11-21
IL143233A (en) 2007-07-24
EP1588706B1 (en) 2011-09-14
IL179015A0 (en) 2007-03-08
PL349424A1 (en) 2002-07-29
SI1140071T1 (sl) 2007-08-31
NZ511938A (en) 2004-02-27
CN1636561A (zh) 2005-07-13
AU2009220022B2 (en) 2011-11-03
RU2008143545A (ru) 2010-05-10
AU2006203077B2 (en) 2009-10-08
TR200805740T1 (tr) 2010-06-21
HK1038888B (en) 2007-09-21
EP1140071A1 (en) 2001-10-10
CY1106581T1 (el) 2012-01-25
HK1038888A1 (en) 2002-04-04
ATE524176T1 (de) 2011-09-15
NO20013143L (no) 2001-08-16
ID29856A (id) 2001-10-18
CA2622805C (en) 2011-05-10
TR200805275T2 (tr) 2008-09-22
ES2373556T3 (es) 2012-02-06
JP5254258B2 (ja) 2013-08-07
NZ553010A (en) 2008-09-26
EP1588706A3 (en) 2005-12-07
TR200605472T1 (tr) 2007-02-21
KR20010089681A (ko) 2001-10-08
HUP0104780A3 (en) 2002-11-28
SI1588706T1 (sl) 2012-01-31
NO328775B1 (no) 2010-05-10
EP2298298A2 (en) 2011-03-23
JP2010090169A (ja) 2010-04-22
PL199100B1 (pl) 2008-08-29

Similar Documents

Publication Publication Date Title
BR9916576A (pt) Uso de antagonista receptor at-1 ou modulador receptor at-2 para o tratamento de doenças associadas com um aumento de receptores at-1 ou at-2
BR0213358A (pt) Uso de flibanserina
SV2003001107A (es) Imidazotriazinas ref.lea 35368
MY117251A (en) Use of central cannabinoid receptor antagonists for the preparation of drugs
EP1539246A4 (en) ADMINISTRATION IN THE CENTRAL AIRWAYS FOR THE SYSTEMIC DELIVERY OF THERAPEUTICS
BR9913457A (pt) Neuroproteção
BR0314488A (pt) Composto, composição farmacêutica e métodos de tratamento
BR9909138A (pt) Combinação para o tratamento de dependência de álcool e drogas contendo um antagonista de opióide e um modulador de complexo receptor de nmda
BR9810337A (pt) Utilização de um antagonista especìfico dos receptores 5ht2 para a preparação de medicamentos úteis no tratamento da sìndrome de apnéia do sono
BR9912588A (pt) Prevenção de recorrência de enxaqueca
BR0007686A (pt) Uso de antagonistas receptores da angiotensina ii para tratar enfartação miocárdia aguda
BR0214798A (pt) Uso de anastrozol ou um sal farmaceuticamente aceitável do mesmo, e, métodos para reduzir a taxa de recorrência de câncer e a taxa de um novo tumor primário contralateral em uma mulher pós-menopausa tendo câncer de mama em estado inicial
BR0010092A (pt) Composto, preparação farmacêutica para a administração oral ou parenteral, uso de um composto, e, uso da preparação farmacêutica
BR9812404A (pt) Combinação de um antagonista de endotelina, preparação farmacêutica, processo para preparar uma preparação farmacêutica, e , uso de uma combinação de um bloqueador de beta receptor e de um antagonista de endotelina
AU8553898A (en) Use of 2,3-benzodiazepine derivatives for the preparation of pharmaceutical compositions to treat diseases connected with the endogenous opioid system
BR0011845A (pt) Complexo farmacêutico
WO1999049892A3 (fr) Utilisation de conjugues p40 actifs par voie nasale
IL154777A0 (en) Il-6 receptor/il-6 chimera in huntington's disease
BR0104005A (pt) Composição farmacêutica para a prevenção ou para o tratamento de uma doença associada com um excesso de produção de il-2
BR0013921A (pt) Composições farmacêuticas para tratamento de psorìase
BR9805026A (pt) Compostos contdndo tetrahidrolipstatina
BR9609937A (pt) Composição contendo ácido mefenâmico em associação com codeìna
ITMI20011634A1 (it) Uso dei derivati dell'acido idrossamico per la preparazione di medicamenti anti-tumorali

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 13 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 16A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.